{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:05:52Z","timestamp":1794027952104,"version":"4.8.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is now standard for matched unrelated donor (MUD) hematopoietic cell transplantation (HCT). Previous studies comparing MUD and haploidentical donor HCT using PTCy were limited in size and follow-up. We therefore performed a registry-based analysis examining the impact of donor type on HCT with PTCy. Adult patients (n = 5873) receiving MUD (n = 1973) or haploidentical (n = 3900) HCT with PTCy for acute leukemia (74.2%) or myelodysplastic syndrome (MDS; 25.8%) reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021 were included. Primary end points were 3-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS). Cox regression and sensitivity analyses were performed through adjustment of propensity scores. Haploidentical HCT had worse OS (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.04-1.27; P = .005) and GRFS (HR, 1.19; 95% CI, 1.10-1.29; P&amp;lt; .001) versus MUD HCT. Donor age was the only other donor factor associated with survival. Results were confirmed in sensitivity analysis. When restricted to reduced intensity conditioning or donors &amp;lt;30 years, OS did not differ between groups. Haploidentical HCT was associated with higher primary graft failure (HR, 1.67; P = .002), increased grade 3\/4 acute GVHD (HR, 1.28; P = .039), higher moderate\/severe chronic GVHD (HR, 1.47; P&amp;lt; .001), and nonrelapse mortality (HR, 1.34; P&amp;lt; .001). Grade 2 to 4 acute GVHD and relapse risk did not differ. This large analysis showed that in adults with acute leukemia or MDS, MUD HCT was associated with improved outcomes versus haploidentical HCT with PTCy-based GVHD prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017194","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:21:34Z","timestamp":1759782094000},"page":"233-245","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"first","affiliation":[{"name":"1Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-7651","authenticated-orcid":false,"given":"Yosra M.","family":"Aljawai","sequence":"additional","affiliation":[{"name":"2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-0176","authenticated-orcid":false,"given":"Todd E.","family":"DeFor","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-1162","authenticated-orcid":false,"given":"Caitrin","family":"Bupp","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasweta","family":"Gooptu","sequence":"additional","affiliation":[{"name":"6Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-6836","authenticated-orcid":false,"given":"Antonio M.","family":"Jimenez Jimenez","sequence":"additional","affiliation":[{"name":"7Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix A.","family":"Mensah","sequence":"additional","affiliation":[{"name":"9Indiana Blood and Marrow Transplantation, Franciscan Health, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[{"name":"10Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Shaffer","sequence":"additional","affiliation":[{"name":"11Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen E.","family":"Shaw","sequence":"additional","affiliation":[{"name":"12Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-8252","authenticated-orcid":false,"given":"Stephen R.","family":"Spellman","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Stefanski","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery J.","family":"Auletta","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[{"name":"13Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-4155","authenticated-orcid":false,"given":"Ramzi","family":"Abboud","sequence":"additional","affiliation":[{"name":"14Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"3","key":"2026012009164806500_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026012009164806500_bib2","first-page":"686.e1","article-title":"Existence of HLA-mismatched unrelated donors closes the gap in donor availability regardless of recipientaAncestry","volume":"29","author":"Chowdhury","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"2026012009164806500_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026012009164806500_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"suppl 2","key":"2026012009164806500_bib5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/bmt.2015.92","article-title":"HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide","volume":"50","author":"Fuchs","year":"2015","journal-title":"Bone Marrow Transpl"},{"issue":"16","key":"2026012009164806500_bib6","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2026012009164806500_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026012009164806500_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"18","key":"2026012009164806500_bib9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026012009164806500_bib10","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012009164806500_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026012009164806500_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"2026012009164806500_bib13","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"issue":"282","key":"2026012009164806500_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2026012009164806500_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"3","key":"2026012009164806500_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"25","key":"2026012009164806500_bib17","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"2026012009164806500_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026012009164806500_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026012009164806500_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"2026012009164806500_bib21","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/bloodadvances.2020001620","article-title":"Impact of donor age and kinship on clinical outcomes after T-cell\u2013replete haploidentical transplantation with PT-Cy","volume":"4","author":"Mariotti","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2026012009164806500_bib22","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","article-title":"Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes","volume":"8","author":"Spellman","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"2026012009164806500_bib23","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood.2023023697","article-title":"Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT","volume":"143","author":"Sanz","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026012009164806500_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/bloodadvances.2023011814","article-title":"Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7\/8-matched unrelated donor","volume":"8","author":"Fingerson","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026012009164806500_bib25","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/bmt.2016.162","article-title":"Unrelated donor search prognostic score to support early HLA consultation and clinical decisions","volume":"51","author":"Wadsworth","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2026012009164806500_bib26","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jtct.2023.12.061","article-title":"Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: a report from the BMT CTN 1702 trial","volume":"30","author":"Pidala","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2026012009164806500_bib27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2024-200833","article-title":"Likelihood of finding an 8\/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: primary results from BMT CTN 1702","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026012009164806500_bib28","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non\u2013first-degree related donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026012009164806500_bib29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/bjh.19673","article-title":"Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"205","author":"Aljawai","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"2026012009164806500_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2026012009164806500_bib31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","article-title":"Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years","volume":"53","author":"Debals-Gonthier","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026012009164806500_bib32","first-page":"464.e1","article-title":"Cost-effectiveness of unrelated umbilical cord blood transplantation versus HLA-haploidentical related bone marrow transplantation: evidence from BMT CTN 1101","volume":"29","author":"Ramsey","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2026012009164806500_bib33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/233\/2497030\/blooda_adv-2025-017194-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/233\/2497030\/blooda_adv-2025-017194-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:18:16Z","timestamp":1768918696000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/233\/547589\/Matched-unrelated-vs-haploidentical-donor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017194","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2026,1,5]]}}}